The Chronic Lymphocytic Leukemia Channel is supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver).
The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO 2019 | DUO trial: duvelisib for CLL/SLL
Ian Flinn, MD, PhD, from Tennessee Oncology, Nashville, TN, delivers an update on the DUO trial (NCT02004522) looking at duvelisib for R/R chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), and how PI3K inhibitors will be used in CLL therapy going forward. This interview was recorded at the American Society of Oncology (ASCO) 2019 Annual Meeting, held in Chicago, IL.
